MiMedx Profit Margin 2007-2021 | MDXG
Current and historical gross margin, operating margin and net profit margin for MiMedx (MDXG) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. MiMedx net profit margin as of September 30, 2021 is -12.34%.
|MiMedx Annual Profit Margins
|MiMedx Quarterly Profit Margins
||Medical - Biomedical and Genetics
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.